Cullinan (CGEM): Buy the Cash Cushion and a 2027 FDA Upside — Tactical Swing Trade
Cullinan Therapeutics is a clinical-stage oncology and immuno-oncology company trading at roughly $790M market value while sitting on a large cash position. Positive pivotal data in its zipalertinib program and multiple clinical readouts set up a potential 2027 FDA catalyst. For traders willing to accept clinical binary risk, a mid-term long (45 tr…